Novartis Expands Global Health Push as Kidney Drug Shows 49% Decline Slowdown
SHERIDAN, WYOMING – April 14, 2026 – Novartis has announced a major expansion of its community health programs, aiming to close persistent treatment gaps in heart disease and cancer care across more than 30 countries by 2030. The move comes alongside a striking clinical milestone for its kidney disease drug Fabhalta® and a freshly agreed acquisition in the allergy space, marking an unusually active period for one of the world's largest pharmaceutical companies. With medicines already reaching 296 million people worldwide, Novartis is signaling it intends to push that number significantly higher by the end of the decade.